Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on June 24, 2018. The filing reports the entry into a Material Definitive Agreement with a wholly-owned subsidiary of Gossamer Bio, Inc. (Gossamer). The agreement grants Gossamer an exclusive, sublicensable license to develop and commercialize AKB-4924 and related products globally, focusing initially on ulcerative colitis and Crohn's Disease.
Key Financial Metrics and Transaction Terms
The filing details a significant licensing deal with the following financial components:
- Upfront Payment: $20 million payable by Gossamer to Aerpio.
- Development Milestones: Up to $55 million contingent on specified achievements.
- Commercial Milestones: Up to $85 million contingent on specified achievements.
- Sales Milestones: Up to $260 million contingent on specified achievements.
- Royalties: Tiered royalties ranging from high-single-digit to mid-teens percentages on sales.
- Alternative Consideration: Under certain circumstances (e.g., sublicense or change of control), Aerpio may elect to receive a specified percentage of payments received by Gossamer instead of standard milestones and royalties.
The filing does not provide current revenue, profit, cash flow, or debt figures for Aerpio Pharmaceuticals, Inc., as this is a current report regarding a specific event rather than a periodic financial statement.
Material Changes and Agreement Structure
The primary material change is the transfer of development and commercialization rights for AKB-4924 to Gossamer. Key structural elements include:
- Exclusivity: Aerpio is prohibited from developing or commercializing certain HIF stabilizing compounds outside the agreement, and Gossamer is restricted from developing other HIF stabilizers not permitted under the terms.
- Termination: The agreement terminates on a product-by-product and country-by-country basis, lasting the later of 15 years from first commercial sale or the expiration of valid patent claims. Either party may terminate for material breach or bankruptcy. Gossamer may terminate for safety/efficacy issues, while Aerpio may terminate if Gossamer takes specific actions regarding licensed patents.
- Reversion of Rights: Under certain termination scenarios, Aerpio retains worldwide rights to the terminated program.
Outlook, Risks, and Management Commentary
Management has formed a joint development committee to oversee activities. The agreement includes provisions for Gossamer to use commercially reasonable efforts to develop products in the U.S., two major European countries, and Japan. Risks associated with the transaction include the contingent nature of milestone payments and the potential for termination due to safety, efficacy, or patent disputes. The filing notes that confidential treatment has been requested for portions of the license agreement exhibit.
Investor Verification Checklist
- Verify the exact terms of the "specified percentage" alternative consideration in the event of a Gossamer change of control or sublicense.
- Confirm the specific milestones required to trigger the $55 million in development and $85 million in commercial payments.
- Review the confidential portions of the License Agreement (Exhibit 10.1) filed separately with the SEC for exclusivity carve-outs.
- Monitor the formation and initial activities of the joint development committee.
- Assess the impact of the $20 million upfront payment on Aerpio's immediate liquidity position.